secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001013762-24-002578
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed reports positive long-term preclinical AD study results for INM-901 confirming prior pilot data
--------------------------------------------------------------------------------

- Long-term (7-month) in vivo study confirms cognitive and memory improvements seen in 3-month pilot using 5xFAD amyloidosis model.
- INM-901-treated AD groups achieved statistical significance in certain behavioral assessments vs. placebo.
- Clear dose response observed across Novel Object Recognition, Open Field, Barnes Maze, and other tests.
- Additional molecular analyses (receptor engagement, neuroinflammation, neurogenesis, neuroprotection) are ongoing.
- CMC/GLP studies being planned to support IND submission; INM-901 targets CB1/CB2/PPAR pathways and penetrates BBB.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000101376224002578/0001013762-24-002578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000101376224002578/ea0210292-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001013762-24-002578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer